MA38358A1 - Formulations de composés organiques - Google Patents
Formulations de composés organiquesInfo
- Publication number
- MA38358A1 MA38358A1 MA38358A MA38358A MA38358A1 MA 38358 A1 MA38358 A1 MA 38358A1 MA 38358 A MA38358 A MA 38358A MA 38358 A MA38358 A MA 38358A MA 38358 A1 MA38358 A1 MA 38358A1
- Authority
- MA
- Morocco
- Prior art keywords
- formulations
- organic compounds
- pharmaceutically acceptable
- present
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12136—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/1204—Type of occlusion temporary occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
- A61B2017/12068—Details concerning the detachment of the occluding device from the introduction device detachable by heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
- A61B2017/12086—Details concerning the detachment of the occluding device from the introduction device magnetically detachable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Surgical Instruments (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques solides comprenant le composé inhibiteur de phosphatidylinositol 3-kinase 4-(trifluorométhyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine ou un sel pharmaceutiquement acceptable de celui-ci, du stéaryl-fumarate de sodium, et facultativement au moins un véhicule pharmaceutiquement acceptable additionnel. La présente invention concerne en outre les procédés pour leur préparation et leur utilisation en tant que médicaments pour le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361773492P | 2013-03-06 | 2013-03-06 | |
PCT/IB2014/059424 WO2014136048A1 (fr) | 2013-03-06 | 2014-03-04 | Formulations de composés organiques |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38358A1 true MA38358A1 (fr) | 2016-11-30 |
MA38358B1 MA38358B1 (fr) | 2017-07-31 |
Family
ID=50342366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38358A MA38358B1 (fr) | 2013-03-06 | 2014-03-04 | Formulations de composés organiques |
Country Status (29)
Country | Link |
---|---|
US (2) | US9474534B2 (fr) |
EP (1) | EP2964200B1 (fr) |
JP (1) | JP6313343B2 (fr) |
KR (1) | KR102233757B1 (fr) |
CN (1) | CN105073099B (fr) |
AR (2) | AR095032A1 (fr) |
AU (1) | AU2014224238B2 (fr) |
BR (1) | BR112015021097B1 (fr) |
CA (1) | CA2904032C (fr) |
CL (1) | CL2015002466A1 (fr) |
EA (1) | EA028301B1 (fr) |
ES (1) | ES2634020T3 (fr) |
HK (1) | HK1212244A1 (fr) |
IL (1) | IL240579B (fr) |
JO (1) | JO3256B1 (fr) |
MA (1) | MA38358B1 (fr) |
MX (1) | MX370175B (fr) |
MY (1) | MY174648A (fr) |
NZ (1) | NZ711015A (fr) |
PE (1) | PE20151607A1 (fr) |
PH (1) | PH12015501945A1 (fr) |
PL (1) | PL2964200T3 (fr) |
PT (1) | PT2964200T (fr) |
SG (1) | SG11201506392VA (fr) |
TN (1) | TN2015000386A1 (fr) |
TW (1) | TW201442712A (fr) |
UA (1) | UA114948C2 (fr) |
WO (1) | WO2014136048A1 (fr) |
ZA (1) | ZA201505830B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9498604B2 (en) | 1997-11-12 | 2016-11-22 | Genesis Technologies Llc | Medical device and method |
US9561094B2 (en) | 2010-07-23 | 2017-02-07 | Nfinium Vascular Technologies, Llc | Devices and methods for treating venous diseases |
US20150351775A1 (en) | 2014-06-04 | 2015-12-10 | Nfinium Vascular Technologies, Llc | Low radial force vascular device and method of occlusion |
CN108135854B (zh) * | 2015-06-30 | 2022-03-11 | 基因泰克公司 | 含有药物的立即释放片剂和用于形成片剂的方法 |
WO2022066499A1 (fr) * | 2020-09-27 | 2022-03-31 | Boston Scientific Scimed, Inc. | Dispositifs de guidage expansibles, systèmes, et procédés |
WO2022170187A1 (fr) * | 2021-02-05 | 2022-08-11 | Pyne Devaraj | Dispositif et méthodes d'embolisation à ballonnet détachable |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2164940T3 (es) * | 1995-12-27 | 2002-03-01 | Janssen Pharmaceutica Nv | Forma de dosificacion solida bioadhesiva. |
US5916235A (en) | 1997-08-13 | 1999-06-29 | The Regents Of The University Of California | Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities |
ATE454098T1 (de) * | 1998-02-10 | 2010-01-15 | Artemis Medical Inc | Okklusions-, verankerungs-, span- oder stromsteuergerät |
US6066157A (en) | 1998-09-16 | 2000-05-23 | Medtronics Ave, Inc. | Anchor joint for coaxial balloon dilatation catheter |
US6368338B1 (en) | 1999-03-05 | 2002-04-09 | Board Of Regents, The University Of Texas | Occlusion method and apparatus |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
US7618435B2 (en) * | 2003-03-04 | 2009-11-17 | Nmt Medical, Inc. | Magnetic attachment systems |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
KR20110050549A (ko) * | 2008-09-03 | 2011-05-13 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 이를 포함하는 제약 제제 |
TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
JP2013508370A (ja) * | 2009-10-23 | 2013-03-07 | メルク・シャープ・エンド・ドーム・コーポレイション | ジペプチジルペプチダーゼ−4阻害剤とピオグリタゾンとの組み合わせの医薬組成物 |
US8992540B2 (en) | 2010-07-22 | 2015-03-31 | Kyphon Sarl | Adjustable surgical instruments and methods of use and fabrication |
CA2816957A1 (fr) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions et procedes de traitement de la myelofibrose |
JP6061432B2 (ja) | 2011-06-03 | 2017-01-18 | コヴィディエン リミテッド パートナーシップ | 塞栓インプラント及び動脈閉塞のためのシステム |
WO2014164535A1 (fr) | 2013-03-11 | 2014-10-09 | Ferry Steven J | Fil-guide/dispositif d'occlusion partielle pour course intraluminale |
-
2014
- 2014-03-04 KR KR1020157023903A patent/KR102233757B1/ko active IP Right Grant
- 2014-03-04 MY MYPI2015702599A patent/MY174648A/en unknown
- 2014-03-04 SG SG11201506392VA patent/SG11201506392VA/en unknown
- 2014-03-04 JP JP2015560827A patent/JP6313343B2/ja active Active
- 2014-03-04 JO JOP/2014/0069A patent/JO3256B1/ar active
- 2014-03-04 MX MX2015011705A patent/MX370175B/es active IP Right Grant
- 2014-03-04 UA UAA201508151A patent/UA114948C2/uk unknown
- 2014-03-04 PT PT147116131T patent/PT2964200T/pt unknown
- 2014-03-04 US US14/771,908 patent/US9474534B2/en active Active
- 2014-03-04 EP EP14711613.1A patent/EP2964200B1/fr active Active
- 2014-03-04 ES ES14711613.1T patent/ES2634020T3/es active Active
- 2014-03-04 AU AU2014224238A patent/AU2014224238B2/en active Active
- 2014-03-04 PL PL14711613T patent/PL2964200T3/pl unknown
- 2014-03-04 NZ NZ711015A patent/NZ711015A/en unknown
- 2014-03-04 MA MA38358A patent/MA38358B1/fr unknown
- 2014-03-04 CA CA2904032A patent/CA2904032C/fr active Active
- 2014-03-04 EA EA201591649A patent/EA028301B1/ru not_active IP Right Cessation
- 2014-03-04 WO PCT/IB2014/059424 patent/WO2014136048A1/fr active Application Filing
- 2014-03-04 CN CN201480011950.2A patent/CN105073099B/zh active Active
- 2014-03-04 PE PE2015001869A patent/PE20151607A1/es not_active Application Discontinuation
- 2014-03-04 BR BR112015021097-0A patent/BR112015021097B1/pt active IP Right Grant
- 2014-03-05 TW TW103107542A patent/TW201442712A/zh unknown
- 2014-03-06 AR ARP140100730A patent/AR095032A1/es not_active Application Discontinuation
- 2014-03-10 US US14/774,775 patent/US10342547B2/en active Active
-
2015
- 2015-08-12 ZA ZA2015/05830A patent/ZA201505830B/en unknown
- 2015-08-13 IL IL240579A patent/IL240579B/en active IP Right Grant
- 2015-09-03 PH PH12015501945A patent/PH12015501945A1/en unknown
- 2015-09-03 TN TN2015000386A patent/TN2015000386A1/en unknown
- 2015-09-04 CL CL2015002466A patent/CL2015002466A1/es unknown
-
2016
- 2016-01-13 HK HK16100341.8A patent/HK1212244A1/xx unknown
-
2023
- 2023-02-06 AR ARP230100279A patent/AR128459A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38358A1 (fr) | Formulations de composés organiques | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
MA40523A (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA40769B1 (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
BR112018011376A2 (pt) | composição farmacêutica que compreende um inibi-dor de urat1 potente | |
MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA39163B1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux | |
MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives | |
MA38973A1 (fr) | Aminohétéroaryles benzamides en tant qu'inhibiteurs de kinase | |
MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses |